Relevant bibliographies by topics / Metronomica

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Metronomica'

Author: Grafiati
Published: 9 March 2023
Last updated: 10 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Metronomica.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Metronomica"

1

Orlandi, Armando, Elena Iattoni, Carmela Di Dio, and Maria Alessandra Calegari. "Efficacia duratura e ottima tollerabilità di lapatinib associato a capecitabina metronomica in due pazienti con carcinoma mammario HER2-positivo." AboutOpen 3, no. 1 (December 29, 2017): 112–16. http://dx.doi.org/10.19156/abtpn.2017.0026.

Full text
Abstract:
L’utilizzo di lapatinib in combinazione con capecitabina è associato in alcune pazienti a tossicità gastrointestinale e cutanea, che ne compromette la regolare assunzione limitando l’utilizzo di un’efficace schedula terapeutica nel carcinoma metastatico della mammella HER2-positivo, refrattario al trattamento con trastuzumab. I due casi clinici presentati mostrano il buon profilo di tossicità e l’efficacia della combinazione lapatinib (1250 mg/die) + capecitabina metronomica (500 mg 3 volte/die) (Oncology).
APA, Harvard, Vancouver, ISO, and other styles
2

Arvat, Emanuela. "Impiego della chemioterapia metronomica in pazienti con carcinoma surrenalico metastatico sottoposti a multipli trattamenti precedenti." L'Endocrinologo 15, no. 5 (September 25, 2014): 240. http://dx.doi.org/10.1007/s40619-014-0074-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Revon-Rivière, Gabriel, Shripad Banavali, Laila Heississen, Wendy Gomez Garcia, Babak Abdolkarimi, Manickavallie Vaithilingum, Chi-Kong Li, et al. "Metronomic Chemotherapy for Children in Low- and Middle-Income Countries: Survey of Current Practices and Opinions of Pediatric Oncologists." Journal of Global Oncology, no. 5 (December 2019): 1–8. http://dx.doi.org/10.1200/jgo.18.00244.

Full text
Abstract:
PURPOSE Low- and middle-income countries (LMICs) experience the burden of 80% of new childhood cancer cases worldwide, with cure rates as low as 10% in some countries. Metronomics combines frequent administrations of low-dose chemotherapy with drug repurposing, which consists of using already-approved drugs for new medical applications. With wide availability, limited costs, and little infrastructure needs, metronomics can be part of constraint-adapted regimens in these resource-limited settings—with the understanding that metronomics shall not be a substitute for standard treatments when available and doable. Our study aims to describe the experience, practices, opinions, and needs in metronomics of physicians working in LMICs. METHODS An online questionnaire was sent to more than 1,200 physicians in pediatric oncology networks in LMICs. Items included the type of center, physician’s demographics, experience in pediatric oncology, and experience with current knowledge of metronomics. Opinions and perspectives were explored using multiple-answer and open questions. RESULTS Of physicians, 17% responded. Of respondents, 54.9% declared that they had already used a metronomic regimen. The most frequently cited repositioned drugs were celecoxib (44%) followed by propranolol and valproic acid (17%). Respondents highlighted the advantages of outpatient use (20%) and expected low toxicity (24%). In considering the drawbacks of metronomics, 47% of responses highlighted the lack of scientific evidence or guidelines, 33% the availability or affordability of drugs, and 18% the problem of acceptance or compliance. Of physicians, 79% believed that use of metronomics will spread in LMICs in the near future and 98% of them were willing to participate in international metronomic protocols or registries. CONCLUSION Metronomics is already used in LMICs and is a potential answer to unmet needs in pediatric oncology. There is room for improvement in the availability of drugs and a necessity to develop collaborative protocols and research to generate level A evidence.
APA, Harvard, Vancouver, ISO, and other styles
4

Svoboda, Tomáš. "Metronomic chemotherapy in breast cancer." Onkologie 10, no. 4 (August 1, 2016): 161–65. http://dx.doi.org/10.36290/xon.2016.035.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Teixeira, N. C. T., A. P. C. V. Bicalho, A. V. Vasconcelos, R. S. Horta, R. M. C. Cunha, and G. E. Lavalle. "Ciclooxygenase inhibitor and metronomic chemotherapy association for the treatment of metastatic anal sac carcinoma in dog: case report." Arquivo Brasileiro de Medicina Veterinária e Zootecnia 68, no. 4 (August 2016): 913–18. http://dx.doi.org/10.1590/1678-4162-8439.

Full text
Abstract:
ABSTRACT Metronomic chemotherapy consists of an anticancer modality treatment. It is applicable in patients at an advanced stage, with the objective of increasing overall survival. The aim of this study was to report an anal sac apocrine carcinoma case in a dog with lymph node metastasis treated with metronomic chemotherapy sequential to surgery and conventional chemotherapy using gemcitabine and carboplatin. Metronomic chemotherapy was associated with cyclooxygenase-2 (COX-2) inhibitors, due to strong tumor COX-2 immunohistochemistry expression. Metronomic chemotherapy was initiated with cyclophosphamide, but it was replaced by lomustine, also in metronomic dosage, due to adverse effects. Treatment showed effectiveness, since the patient's overall survival exceeded 1095 days (36 months), considerably higher than the mean overall survival expected for this pathology.
APA, Harvard, Vancouver, ISO, and other styles
6

Olovnikov, Alexey M. "Planetary Metronome as a Regulator of Lifespan and Aging Rate: The Metronomic Hypothesis." Biochemistry (Moscow) 87, no. 12-13 (December 2022): 1640–50. http://dx.doi.org/10.1134/s0006297922120197.

Full text
Abstract:
Abstract A metronomic mechanism for the duration control of ontogenetic cycle periods of an animal is proposed. The components of the proposed metronomic system include the ventricular system of the brain, planet Earth as a generator of metronomic signals, and temporal DNA (tDNA) as a substrate that is epigenetically marked to measure elapsed time of ontogenesis. The metronomic system generates repetitive signals in the form of hydrodynamic disturbances in the cerebrospinal fluid (CSF). The metronomic effect arises due to the superposition of two processes – the near-wall unidirectional flow of CSF and oscillations in the movement of the planet. Hydrodynamic impacts of the metronome are transformed into nerve impulses that initiate epigenetic modification of tDNA in neurons, changing the content of factors expressed by this DNA for innervated targets of the body. The duration of ontogenetic cycle periods, including duration of the adult life, depends on the rate of addition of epigenetic marks to tDNA. This rate depends mainly on the frequency of the metronomic signals used by each particular species. But epigenetic modifications can also be influenced by factors that modulate metabolism and the rate of chromatin modifications, such as a calorie-restricted diet.
APA, Harvard, Vancouver, ISO, and other styles
7

Su, Nai-Wen, and Yu-Jen Chen. "Metronomic Therapy in Oral Squamous Cell Carcinoma." Journal of Clinical Medicine 10, no. 13 (June 26, 2021): 2818. http://dx.doi.org/10.3390/jcm10132818.

Full text
Abstract:
Metronomic therapy is characterized by drug administration in a low-dose, repeated, and regular manner without prolonged drug-free interval. The two main anticancer mechanisms of metronomic therapy are antiangiogenesis and immunomodulation, which have been demonstrated in several delicate in vitro and in vivo experiments. In contrast to the traditional maximum tolerated dose (MTD) dosing of chemotherapy, metronomic therapy possesses comparative efficacy but greatlydecreases the incidence and severity of treatment side-effects. Clinical trials of metronomic anticancer treatment have revealed promising results in a variety cancer types and specific patient populations such as the elderly and pediatric malignancies. Oral cavity squamous cell carcinoma (OCSCC) is an important health issue in many areas around the world. Long-term survival is about 50% in locally advanced disease despite having high-intensity treatment combined surgery, radiotherapy, and chemotherapy. In this article, we review and summarize the essence of metronomic therapy and focus on its applications in OCSCC treatment.
APA, Harvard, Vancouver, ISO, and other styles
8

Zhang, Mu, Chen Chen, Feng Su, Zhiguo Huang, Xiangmin Li, and Xiaogang Li. "Knockdown of Hypoxia-Inducible Factor 1α Improved the Efficacy of Low-Dose Metronomic Chemotherapy of Paclitaxel in Human Colon Cancer Xenografts." Technology in Cancer Research & Treatment 16, no. 5 (August 29, 2016): 609–19. http://dx.doi.org/10.1177/1533034616665720.

Full text
Abstract:
Low-dose metronomic chemotherapy represents a new strategy for solid tumor treatments with a strong antiangiogenic activity and few side effects. However, low-dose metronomic therapy alone is not always as effective as traditional chemotherapy on eradication of tumor. On the contrary, low-dose metronomic in some cases could stimulate tumor growth due to hypoxia of tumor cells induced during therapy. Our study aimed to investigate whether knockdown of hypoxia-inducible factor-1α expression in tumor cell could facilitate low-dose metronomic therapy with paclitaxel for human colon cancer. Human colon cancer cell line (HT-29) stably transfected with specific short hairpin RNAs silencing hypoxia-inducible factor-1α exhibited marked attenuation of hypoxia-induced expression of the target genes such as vascular endothelial growth factor, glucose transporter 1, and P-glycoprotein. Compared with HT-29-c xenograft tumor model established by subcutaneous injection of HT-29 cells stably transfected with scrambled control short hairpin RNA, HT-29-ih xenograft tumor model showed more significant and long-lasting antitumor responses of empirical metronomic paclitaxel regimens, accompanied by drastic angiogenesis decrease and neglectable toxicity. All these data indicated that the combination of paclitaxel low-dose metronomic therapy with hypoxia-inducible factor-1α knockdown might provide a potent battle against colon cancer.
APA, Harvard, Vancouver, ISO, and other styles
9

Cazzaniga, Marina Elena, Nicoletta Cordani, Serena Capici, Viola Cogliati, Francesca Riva, and Maria Grazia Cerrito. "Metronomic Chemotherapy." Cancers 13, no. 9 (May 6, 2021): 2236. http://dx.doi.org/10.3390/cancers13092236.

Full text
Abstract:
Metronomic chemotherapy treatment (mCHT) refers to the chronic administration of low doses chemotherapy that can sustain prolonged, and active plasma levels of drugs, producing favorable tolerability and it is a new promising therapeutic approach in solid and in hematologic tumors. mCHT has not only a direct effect on tumor cells, but also an action on cell microenvironment, by inhibiting tumor angiogenesis, or promoting immune response and for these reasons can be considered a multi-target therapy itself. Here we review the state of the art of mCHT use in some classical tumour types, such as breast and no small cell lung cancer (NSCLC), see what is new regarding most recent data in different cancer types, such as glioblastoma (GBL) and acute myeloid leukemia (AML), and new drugs with potential metronomic administration. Finally, a look at the strategic use of mCHT in the context of health emergencies, or in low –and middle-income countries (LMICs), where access to adequate healthcare is often not easy, is mandatory, as we always need to bear in in mind that equity in care must be a compulsory part of our medical work and research.
APA, Harvard, Vancouver, ISO, and other styles
10

Mutsaers, Anthony J. "Metronomic Chemotherapy." Topics in Companion Animal Medicine 24, no. 3 (August 2009): 137–43. http://dx.doi.org/10.1053/j.tcam.2009.03.004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Metronomica"

1

SCAGLIOTTI, ARIANNA. "Analyzing the impact of metronomic scheduling and dosing of 5-Fluorouracil and Vinorelbine in triple-negative breast cancer and endothelial cells." Doctoral thesis, Università degli Studi di Milano-Bicocca, 2021. http://hdl.handle.net/10281/304796.

Full text
Abstract:
Il tumore alla mammella triplo-negativo (TNBC) rappresenta il sottotipo di tumore alla mammella più aggressivo ed è spesso associato ad una breve sopravvivenza libera da malattia. La dose massima tollerata, utilizzata come terapia standard (STD), rimane la prima opzione terapeutica per pazienti con TNBC, anche se non è sufficiente nel bloccare le recidive, le quali rimangono la prima causa di morte per questo tipo di tumore. Recentemente, è stato testato un diverso approccio terapeutico, chiamato chemioterapia metronomica (mCHT), che prevede la continua somministrazione della minima dose biologicamente attiva senza pause libere da farmaco. Ad oggi, i risultati mostrano una forte stabilizzazione della crescita del cancro ed un miglioramento della qualità della vita delle pazienti. La chemioterapia metronomica ha un effetto sia antitumorale che anti-angiogenico. In questa tesi abbiamo indagato, per la prima volta, l’effetto della somministrazione metronomica di 5-Fluorouracile (5-FU) e Vinorelbina (VNR) su linee cellulari di TNBC ed endoteliali, in confronto alla somministrazione STD. In particolare, abbiamo dimostrato che la somministrazione metronomica di 5-FU e VNR, sia in singolo che in combinazione, colpisce le cellule endoteliali e di TNBC a dosi significativamente inferiori della terapia STD. Nonostante le bassi dosi utilizzate, la somministrazione metronomica di 5-FU+VNR è più efficiente della STD nell’inibire la migrazione cellulare e la formazione di colonie sia delle cellule endoteliali che delle cellule TNBC. Per simulare l’interazione tra cellule endoteliali e TNBC, abbiamo utilizzato una co-coltura indiretta. I risultati della co-coltura indiretta mostrano che il terreno condizionato dalle cellule TNBC trattate con 5-FU+VNR secondo protocollo metronomico bloccano completamente la migrazione e la formazione di colonie delle cellule endoteliali. Inoltre, abbiamo evidenziato la dipendenza del meccanismo di morte cellulare delle cellule endoteliali e TNBC dalla modalità di somministrazione dei farmaci. In particolare, la combinazione metronomica promuove l’apoptosi nelle cellule endoteliali, mentre nelle cellule TNBC cambia la modalità di morte cellulare dall’apoptosi, indotta dalla terapia STD, all’autofagia, attivando anche la senescenza cellulare. In conclusione, la somministrazione metronomica di 5-FU+VNR è più efficiente della STD nel controllare la proliferazione, la migrazione e la capacità di ricrescita dopo trattamento delle cellule endoteliali e TNBC, suggerendo un miglior controllo sulla crescita tumorale e sulla formazione di recidive. Questi dati evidenziano inoltre i meccanismi molecolari alla base della migliore efficacia della terapia metronomica rispetto alla standard.
Triple-negative breast cancer (TNBC) represents the most malignant subtype of breast cancer, often associated with short disease-free survival. The maximum tolerated dose, used as standard-of-care chemotherapy (STD), remains the primary therapeutic option for TNBC patients, even though it fails to block distant recurrences, which is the first cause of death. Recently, it has been tested a different therapeutic approach, called metronomic chemotherapy (mCHT), where the minimum biological effective dose of the chemotherapeutic agent is given as a continuous administration without drug-free breaks. So far, the results show a strong stabilization of cancer growth and improved cancer patients’ quality of life. mCHT has direct cytotoxic effects on tumors and inhibits endothelial cell proliferation. In this thesis we investigated, for the first time, the effect of the mCHT administration of 5-Fluorouracil (5-FU) plus Vinorelbine (VNR) in endothelial and TNBC cell lines in comparison to the STD treatment. In particular, it has been shown that the mCHT administration of 5-FU and VNR both in single and in combination affects endothelial and TNBC cells at doses significantly lower than the STD one. Despite the low doses used, mCHT 5-FU+VNR is more effective than the STD in inhibiting cell migration and colony formation of both endothelial and TNBC cells. To simulate TNBC and endothelial cells' crosstalk, we utilized an indirect co-culture, which showed that medium conditioned by TNBC cells treated with mCHT 5-FU+VNR completely blocks endothelial cells migration and colony formation. We also pointed out that the modality of cell death of endothelial and TNBC cells depends on the schedule of treatment. In particular, the mCHT combination promotes endothelial’ apoptosis, whereas TNBC switches the modality of cell death from apoptosis, induced by STD, to autophagy, also activating senescence. In conclusion, mCHT 5-FU+VNR is more efficient than the STD in controlling cell proliferation, migration, and regrowth capacity after treatment of HUVECs and TNBC cells, suggesting better control of tumor growth and relapses. These data also highlight the molecular mechanisms that underlie the best efficacy of metronomic therapy towards the standard one.
APA, Harvard, Vancouver, ISO, and other styles
2

Murray, Alexandra M. "Novel anti-endothelial therapeutic strategies in malignant melanoma : the metronomic approach." Thesis, University of Hull, 2011. http://hydra.hull.ac.uk/resources/hull:5288.

Full text
Abstract:
Treatment strategies for advanced malignancy remain limited in their success, despite major advances in the understanding of cancer aetiology and molecular biology. The incidence of many cancers, including melanoma, continues to rise, with a huge demand for therapies even if treatment goals are purely cytostatic. One particular therapeutic strategy is the metronomic (continuous and low) dosing of conventional chemotherapy. There is evidence to suggest that tumour vasculature is the main target of this dosing schedule resulting in an overall 'non specific' anti-angiogenic effect. It is now being studied in clinical trials alone and in combination with specific anti- angiogenic agents. This thesis had two main aims: firstly to investigate the additive or synergistic anti- endothelial effects of a number of conventional cytotoxic agents (Temozolomide, Paclitaxel, Vinorelbine, Etoposide, Carboplatin) in vitro given in a metronomic schedule in combination with a specific anti-angiogenic compound (Sorafenib) and a non-specific sompound (Combretastatin). The anti-proliferative, cytotoxic activities of the metronomic combinatorial schedules were assessed on microvascular endothelial cells and cancer cells usmg an MTT proliferation assay. Results confirmed significant (p
APA, Harvard, Vancouver, ISO, and other styles
3

Bonus, Alexander Evan. "The Metronomic Performance Practice: A History of Rhythm, Metronomes, and the Mechanization of Musicality." Case Western Reserve University School of Graduate Studies / OhioLINK, 2010. http://rave.ohiolink.edu/etdc/view?acc_num=case1270221548.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Kubisch, Rebekka. "Mechanism of cancer evading metronomic chemotherapy and action of Archazolid as an anti-metastatic drug." Diss., Ludwig-Maximilians-Universität München, 2013. http://nbn-resolving.de/urn:nbn:de:bvb:19-158654.

Full text
Abstract:
In the present study the mechanisms leading to acquired chemoresistance, as well as new treatment strategies implying the prevention evading of tumor cells were addressed. Resistance formation is one of the major hurdles in cancer therapy. Metronomic antiangiogenic treatment of xenografted prostate cancer tumors in mice with cyclophosphamide (CPA) results in the appearance of resistant tumors. To investigate the complex molecular changes occurring during resistance formation, a comprehensive gene expression analysis of the resistant tumors in vivo was performed. A multitude of differentially expressed genes, e.g. PAS domain containing protein 1 (PASD1), annexin A3 (ANXA3), neurotensin (NTS) or plasminogen activator tissue (PLAT), were observed, when comparing resistant to in vivo passaged tumor samples. Moreover, tumor cells from in vivo and in vitro conditions showed a significant difference in target gene expression. For clarification of the mechanisms leading to the survival of tumor cells during maintained anti-angiogenic CPA therapy the differentially expressed genes were assigned to functional pathways like: axon guidance, steroid biosynthesis and complement and coagulation cascades. As blood flow might play a crucial role during maintained anti-angiogenic therapy, further analysis was focused on the genes grouped in complement and coagulation cascades. pregulation of anti-coagulatory ANXA3 and PLAT and downregulation of SERPIN A1 and other SERPIN-family members was shown by qPCR analysis. In contrast coagulation factor F3 was upregulated, accompanied by the expression of an altered gene product. Taken together, a potential role of anticoagulation as a resistance mechanism for anti-angiogenic CPA therapy could be described. Furthermore, the role of archazolid, a novel myxobacterial V-ATPase inhibitor in cancer treatment and in particular its action on the secreted cellular proteome was evaluated. As extracellular protein secretion may have an impact on invasive properties of tumor cells, the changes of the secretome profile of highly migratory urinary bladder carcinoma cells upon archazolid treatment were analyzed. An induced secretion of prometastatic lysosomal proteins such as the cathepsin family was observed. Interestingly, intracellular cathepsin B activity however strongly decreases and mature cathepsin B protein diminishes. It could be shown that archazolid inhibits the mannose-6-phosphate receptor mediated trafficking of procathepsin B from the trans-Golgi network to prelysosomal compartments, leading to an impaired cathepsin B maturation process. This results in an unnatural secretion of the inactive proenzyme and a dramatic decrease in intracellular cathepsin B activity. Importantly, also in vivo an archazolid induced reduction of cathepsin B activity was proven and archazolid treatment resulted in a reduced formation of distant metastases in the lungs. In summary these results indicate that archazolid in addition to its known anti-migratory properties might exert an anti-metastatic effect by reducing the activity of pro metastatic proteases like cathepsin B.
APA, Harvard, Vancouver, ISO, and other styles
5

Mendes, Analy Ramos [UNESP]. "Avaliação da quimioterapia metronômica em carcinomas mamários de cadelas por imunomarcações." Universidade Estadual Paulista (UNESP), 2014. http://hdl.handle.net/11449/128087.

Full text
Abstract:
Made available in DSpace on 2015-10-06T13:03:14Z (GMT). No. of bitstreams: 0 Previous issue date: 2014-08-15. Added 1 bitstream(s) on 2015-10-06T13:18:49Z : No. of bitstreams: 1 000848999.pdf: 1544826 bytes, checksum: 3fb73afedffc7650ac4620d6a79c29e9 (MD5)
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
The canine mammary tumor (CMT) is the neoplasia that most commonly affects not spayed bitches. Therapy for CMT is a challenge since there are not described effective treatments for high-grade tumors. A therapeutic option that slows down tumor angiogenesis is metronomic chemotherapy (MC). Quantification of tumor angiogenesis has been proposed by measuring the vascular endothelial growth factor (VEGF) and microvessel density (MVD). Thus, in this study, the response of canine mammary carcinomas by the MC was evaluated by the measurement of MVD and tissue VEGF detection, apoptotic index (AI) and cell proliferation index (PI). Twenty-eight dogs with malignant CMT, equally distributed into a control group (CG) treated with mastectomy and a treated group (TG) treated with MC (cyclophosphamide 15mg/m2 and piroxicam 0.3 mg/kg) both orally and daily for 28 days followed by mastectomy. Mammary tumors were classified and graded histologically. MVD, tissue VEGF, AI and PI of all malignancies were obtained by immunostaining. The analysis showed statistical difference between groups in MVD and AI (p <0.05), showing quantitative reduction in tumor microvasculature and increase in tumor cells apoptosis. Based on this result, we can affirm that MC has antiangiogenic and proapoptotic effects in mammary carcinomas of bitches and can be used as a new therapeutic option
APA, Harvard, Vancouver, ISO, and other styles
6

Mendes, Analy Ramos. "Avaliação da quimioterapia metronômica em carcinomas mamários de cadelas por imunomarcações /." Araçatuba, 2014. http://hdl.handle.net/11449/128087.

Full text
Abstract:
Resumo:A neoplasia mamária canina (NMC) é o tipo de neoplasia que mais comumente afeta cadelas não castradas. A terapia para a NMC é um desafio já que não são descritos tratamentos efetivos para neoplasias de alto grau histológico. Uma possibilidade terapêutica que age diminuindo a angiogênese tumoral é a quimioterapia metronômica (QM). Tem sido proposta a quantificação da angiogênese tumoral através da mensuração do fator de crescimento endotelial vascular (VEGF) e da densidade microvascular (DMV). Desta forma, neste estudo, foi avaliada a resposta de carcinomas mamários caninos à QM por mensuração da DMV e detecção do VEGF tecidual, índice apoptótico (IA) e índice de proliferação celular (IP). Foram utilizadas 28 cadelas com carcinomas mamários, distribuídas igualmente em um grupo controle (GC) tratadas com mastectomia e um grupo tratado (GT) com QM (ciclofosfamida 15mg/m2 e piroxicam 0,3mg/kg) ambos por via oral e diariamente durante 28 dias seguido de mastectomia. As neoplasias mamárias foram classificadas e graduadas histologicamente. DMV, grau do VEGF tecidual, IA e IP de todas as neoplasias foram obtidas por imunomarcação. A análise estatística mostrou diferença entre os grupos na DMV e IA (p<0.05), evidenciando redução quantitativa na microvasculatura tumoral e aumento na apoptose de células neoplásicas. Com base neste resultado, é possível afirmar que a QM possui efeitos antiangiogênicos e pró-apoptóticos em carcinomas mamários de cadelas e pode ser utilizada como uma nova opção terapêutica
Abstract:The canine mammary tumor (CMT) is the neoplasia that most commonly affects not spayed bitches. Therapy for CMT is a challenge since there are not described effective treatments for high-grade tumors. A therapeutic option that slows down tumor angiogenesis is metronomic chemotherapy (MC). Quantification of tumor angiogenesis has been proposed by measuring the vascular endothelial growth factor (VEGF) and microvessel density (MVD). Thus, in this study, the response of canine mammary carcinomas by the MC was evaluated by the measurement of MVD and tissue VEGF detection, apoptotic index (AI) and cell proliferation index (PI). Twenty-eight dogs with malignant CMT, equally distributed into a control group (CG) treated with mastectomy and a treated group (TG) treated with MC (cyclophosphamide 15mg/m2 and piroxicam 0.3 mg/kg) both orally and daily for 28 days followed by mastectomy. Mammary tumors were classified and graded histologically. MVD, tissue VEGF, AI and PI of all malignancies were obtained by immunostaining. The analysis showed statistical difference between groups in MVD and AI (p <0.05), showing quantitative reduction in tumor microvasculature and increase in tumor cells apoptosis. Based on this result, we can affirm that MC has antiangiogenic and proapoptotic effects in mammary carcinomas of bitches and can be used as a new therapeutic option
Orientador:Alexandre Lima de Andrade
Banca:Sabryna Gouveia Calazans
Banca:Maria Cecilia Rui Luvizotto
Mestre
APA, Harvard, Vancouver, ISO, and other styles
7

Lam, Thomas B. L. "Development of a novel anti-endothelial therapeutic strategy combining metronomic chemotherapy dosing with VRGFR-2 inhibition." Thesis, University of Hull, 2005. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.421989.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Sá, Ana Isabel da Silva. "Avaliação dos efeitos secundários induzidos pela administração oral de ciclofosfamida em regime de quimioterapia metronómica em cães e gatos : estudo retrospetivo de 36 casos." Master's thesis, Universidade de Lisboa, Faculdade de Medicina Veterinária, 2016. http://hdl.handle.net/10400.5/12006.

Full text
Abstract:
Dissertação de Mestrado Integrado em Medicina Veterinária
A quimioterapia metronómica (QM) consiste na administração de baixas doses de compostos citotóxicos, de forma contínua, sem pausa, por um longo período de tempo. O fármaco citostático mais utilizado em QM é a ciclofosfamida (CIC). Este estudo teve como objetivo avaliar os efeitos adversos induzidos pela QM com CIC, administrada por via oral, em cães e gatos, diagnosticados com neoplasias malignas, através da caracterização dos efeitos secundários manifestados. Incluiram-se todos os cães e gatos, machos e fêmeas, submetidos a tratamento quimioterápico de neoplasias malignas espontâneas, com doses baixas de CIC, tanto em monoterapia como em terapia combinada (meloxicam, piroxicam e toceranib) no Hospital Veterinário Berna, desde de março de 2014 a março de 2016. Verificou-se que 26 em 36 animais ocorreu pelo menos um efeito adverso relacionado com a QM, correspondente a 72,2% da amostra. Foram observados 101 efeitos adversos, o que correspondeu a 40 episódios de toxicidade gastrointestinal, 30 de mielotoxicidade, 16 de toxicidade hepática, 13 de toxicidade renal e 2 de cistite hemorrágica estéril. Em 18 animais observou-se a ocorrência de mais do que um efeito secundário em simultâneo, ao longo do tratamento, correspondendo a 50% da amostra. No que diz respeito à gravidade dos episódios observados, a maioria destes foram ligeiros, de acordo com o Veterinary cooperative group – common terminology criteria for adverse events (VCOG-CTCAE, 2011), dado que 60,4% dos episódios classificaram-se em grau 1 e 27,72% em grau 2. Apenas a 8,91% e 2,97% dos episódios foi atribuída a classificação em graus 3 e 4, respetivamente.
ABSTRACT - Clinical profile evaluation of toxicity after oral administration of cyclophosphamide in metronomic chemotherapy regimen in dogs and cats - retrospective study of 36 cases - The metronomic chemotherapy (MC) consists in the administration of cytotoxic drugs, continuously, without interruption, using doses lower than those conventionally used. The most widely used cytostatic drug, in MC, is cyclophosphamide (CYC). This study aimed to evaluate the clinical presentation of toxicity induced by the MC with CYC, orally administered in dogs and cats diagnosed with malignant neoplasms, through the characterization of the manifested side effects. In this study were included all cats and dogs, males and females, from Hospital Veterinário Berna, since March 2014 until March 2016, undergoing chemotherapy treatment of spontaneous malignancies with low doses of CYC, either solely or in combination with other drugs (meloxicam, piroxicam and toceranib). It was found that 26 out of 36 animals experienced at least one episode of toxicity associated with MC, corresponding to 72.2% of the animals. 101 events of toxicity were observed, which corresponded to 40 episodes of gastrointestinal toxicity, 30 of myelotoxicity, 16 of hepatotoxicity, 13 of nephrotoxicity and 2 of sterile hemorrhagic cystitis. In 18 animals more than one event of toxicity occured simultaneously, throughout the treatment, corresponding to 50% of the animals. With regard to the severity of the adverse events observed, most of them were mild in accordance with Veterinary Cooperative Group - Common Terminology Criteria for Adverse Events (CTCAE VCOG - 2011), once 60.4% of the events were classsified in grade 1 and 27.72 % in grade 2. Only 8.91 % and 2.97 % of the episodes were classified as grades 3 and 4, respectively.
APA, Harvard, Vancouver, ISO, and other styles
9

Marighetti, P. "RESIDUAL DORMANT CANCER STEM CELL FOCI ARE RESPONSIBLE FOR TUMOR RELAPSE AFTER ANGIOGENIC METRONOMIC THERAPY IN HEPATOCELLULAR CARCINOMA XENOGRAFTS." Doctoral thesis, Università degli Studi di Milano, 2012. http://hdl.handle.net/2434/169919.

Full text
Abstract:
Hepatocellular carcinoma (HCC) is the fifth most common solid tumor and the third leading cause of cancer-related death. Current available chemotherapeutic options are not curative due in part to their resistance to conventional therapies. We have generated orthotopic HCC mouse models in immunodeficient NOD/SCID/IL2rγ null mice by injection of AFP- and/or luciferase-expressing HCC cell lines and primary cells from patients, where tumor growth and spread can be accurately monitored in a non-invasive way. Low dose metronomic administration of cyclophosphamide (LDM-CTX) causes in this model complete regression of the tumor mass with a significant increase in survival (p<0.0001), and reduction in aberrant angiogenesis, IL-6 and TNFα (but not VEGF) levels, hyperproliferation, and alteration of normal liver parenchyma, compared to untreated animals. However, the presence of residual circulating hAFP levels suggested that some tumor cells were still present in livers of treated mice. Immunohistochemistry revealed that those cells had a hAFP+/CD13+/PCNA- phenotype, suggesting that they were dormant cancer stem cells (CSC). Indeed, off-therapy mice developed rapidly tumor growth, which was still sensitive to LDM-CTX therapy. The capacity of developing hepatoshperes in vitro was drastically reduced upon LDM-CTX treatment, which resulted in selection of CD13+ cells, showing that these cells are particularly resistant to therapy. Co-treatment of the CD13-targeting drug bestatin with LDM-CTX resulted in a dramatic reduction in tumor burden. Therefore, our results demonstrate the therapeutic efficacy of administering LDM-CTX and targeting the residual CD13+ CSC-like population in these novel orthotopic HCC models, and strongly suggests that this therapy could be implemented in clinical trials.
APA, Harvard, Vancouver, ISO, and other styles
10

Nim, Rasmus. "Upplevelser av en mobiltelefonapplikations metronoma ljudstimulans under anaeroba intervaller : En experimentell studie med elitfriidrottare." Thesis, Karlstads universitet, Handelshögskolan, 2016. http://urn.kb.se/resolve?urn=urn:nbn:se:kau:diva-39176.

Full text
Abstract:
Syfte: Syftet med denna kandidatuppsats är att förklara de positiva och negativa aspekter elit-friidrottare upplever av mobiltelefonens metronoma ljudstimulans påverkan under anaeroba intervaller, för en eventuell vidareutveckling.Metod: En applikation med grundläggande funktionalitet, som kunde användas vid testtillfället, utvecklades. 8 stycken elitfriidrottare som vid testtillfället hade topp 20 bästa resultat i sin gren, och ålder, i Sverige genomförde 6 anaeroba intervaller utifrån deras eget träningsprogram. Varannan intervall fick de hjälp av mobiltelefonapplikationen och varannan fick de springa som vanligt. Därefter genomfördes öppna intervjuer för att samla in deras upplevelser.Resultat: Applikationen påverkade testpersonernas upplevelser på fyra olika sätt. 1: Mindre ansträngande att springa med samma hastighet. 2: Motiverande vid utmattning. 3: Jämnare löprytm. 4: Försämring vid tappad synkronisering till den metronoma ljudstimulansen.Slutsatser: Applikationen gav mestadels positiva upplevelser hos testpersonerna och har därmed potential att utvecklas till en fullskalig applikation som riktar sig mot elitfriidrottare. För fortsatt-utveckling av applikationen verkar synkronisering till löpningen vara det viktigaste för att löparen ska få en positiv upplevelse.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Metronomica"

1

Bocci, Guido, and Giulio Francia, eds. Metronomic Chemotherapy. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-662-43604-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Pod stuk metronoma. Sankt-Peterburg: Peterburgskiĭ i︠u︡ridicheskiĭ in-t MVD Rossii, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Young, Michael Dunlop. The metronomic society: Natural rhythms and human timetables. London: Thames and Hudson, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Young, Michael Dunlop. The metronomic society: Natural rhythms and human timetables. Cambridge, Mass: Harvard University Press, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Lebesgue, Henri. La Medida De Las Magnitudes / The Measurement of the Magnitudes (Metronomica / Metronomic). Editorial Limusa S.A. De C.V., 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Young, Michael. The Metronomic Society. Harvard University Press, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Bocci, Guido, and Giulio Francia. Metronomic Chemotherapy: Pharmacology and Clinical Applications. Springer Berlin / Heidelberg, 2016.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Bocci, Guido, and Giulio Francia. Metronomic Chemotherapy: Pharmacology and Clinical Applications. Springer, 2014.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Bocci, Guido, and Giulio Francia. Metronomic Chemotherapy: Pharmacology and Clinical Applications. Bocci Guido, 2014.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Scheel, Karl. Grundlagen der Praktischen Metronomie. Vieweg Verlag, Friedr, & Sohn Verlagsgesellschaft mbH, 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Metronomica"

1

Kerbel, Robert S. "Development and Evolution of the Concept of Metronomic Chemotherapy: A Personal Perspective." In Metronomic Chemotherapy, 3–21. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-662-43604-2_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Kong, Doo-Sik, and Do-Hyun Nam. "Clinical Activity of Metronomic Chemotherapy in Central Nervous System Cancers." In Metronomic Chemotherapy, 143–55. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-662-43604-2_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Baluch, Narges, Sushil Kumar, Reza Mokhtari, and Sylvain Baruchel. "Metronomic Chemotherapy in Pediatric Malignancies." In Metronomic Chemotherapy, 157–72. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-662-43604-2_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Praditsuktavorn, Pannee, and Jia Ruan. "Metronomic Chemotherapy in Hematological Malignancies." In Metronomic Chemotherapy, 173–88. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-662-43604-2_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Shao, Yu-Yun, Ann-Lii Cheng, and Chih-Hung Hsu. "Clinical Activity of Metronomic Chemotherapy in Liver Cancers." In Metronomic Chemotherapy, 189–202. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-662-43604-2_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Forte, Victoria A., and Agustin A. Garcia. "Metronomic Chemotherapy in Gynecological Cancers." In Metronomic Chemotherapy, 203–16. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-662-43604-2_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Kotsakis, Athanasios, Nikolaos Kentepozidis, and Vassilis Georgoulias. "Metronomic Chemotherapy in Non-Small-Cell Lung Cancer." In Metronomic Chemotherapy, 217–26. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-662-43604-2_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Bocci, Guido, and Giulio Francia. "Pharmacokinetics and Pharmacogenetics of Metronomic Chemotherapy." In Metronomic Chemotherapy, 229–46. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-662-43604-2_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Snihur, Yuliya, Eddy Pasquier, Graciela Scharovsky, and Nicolas Andre. "Metronomics: Potential Social Impact and New Business Models to Improve Availability of Cancer Treatments." In Metronomic Chemotherapy, 247–61. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-662-43604-2_17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Santos, Keemo Delos, Kelly Lien, Soley Georgsdottir, Lavarnan Sivanathan, and Urban Emmenegger. "Adverse Side Effects Associated with the Use of Low-Dose Metronomic Chemotherapy." In Metronomic Chemotherapy, 263–79. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-662-43604-2_18.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Metronomica"

1

Cho, Youngseok, Seung Woo Chung, and Youngro Byun. "Abstract 2676: Radiotherapy-assisted tumor selective metronomic oral chemotherapy." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-2676.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Mazzucchelli, Serena, Marta Truff, Michela Bellini, Maria A. Rizzuto, Davide Prosperi, and Fabio Corsi. "Metronomic Nanocaged Doxorubicin Prevents Chemoresistance and Cardiotoxicity in Breast Cancer." In The 2nd World Congress on Recent Advances in Nanotechnology. Avestia Publishing, 2017. http://dx.doi.org/10.11159/nddte17.123.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Waxman, David J., Chong-Sheng Chen, Junjie Wu, and Joshua C. Doloff. "Abstract A87: Metronomic chemotherapy activates innate immunity-induced tumor regression." In Abstracts: AACR Special Conference on Tumor Immunology: Multidisciplinary Science Driving Basic and Clinical Advances; December 2-5, 2012; Miami, FL. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.tumimm2012-a87.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Chalasani, Pavani, Livingston B. Robert, Thomas A. Rado, Vijayakrishna K. Gadi, Thomas D. Kummet, Jennifer M. Specht, Alison Stopeck, and Hannah M. Linden. "Abstract OT2-2-05: Metronomic eribulin in metastatic breast cancer." In Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.sabcs14-ot2-2-05.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Peceli, Balint, Daniel Andras Drexler, and Levente Kovacs. "Optimal scheduling of low-dose metronomic chemotherapy: an in-silico analysis." In 2020 IEEE 15th International Conference of System of Systems Engineering (SoSE). IEEE, 2020. http://dx.doi.org/10.1109/sose50414.2020.9130500.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Wilson, Brian C., Stuart K. Bisland, Arjen Bogaards, Annie Lin, Eduardo H. Moriyama, Kai Zhang, and Lothar D. Lilge. "Metronomic photodynamic therapy (mPDT): concepts and technical feasibility in brain tumor." In Biomedical Optics 2003, edited by David Kessel. SPIE, 2003. http://dx.doi.org/10.1117/12.479435.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Tsai, Kelvin K., and Tze-sian Chan. "Abstract A19: Metronomic chemotherapy enhances immunotherapy by preventing stroma-induced immunosuppression." In Abstracts: AACR Special Conference on Tumor Immunology and Immunotherapy; November 27-30, 2018; Miami Beach, FL. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/2326-6074.tumimm18-a19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Ciccolini, Joseph, Eddy Pasquier, Aurelie Lombard, Sarah Giacometti, Christian Faivre, Raphaelle Fanciullino, Cindy Serdjebi, Dominique Barbolosi, and Nicolas Andre. "Abstract 4506: Computational-driven metronomics: application to gemcitabine in neuroblastoma-bearing mice." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-4506.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Bisland, Stuart, Lothar Lilge, Annie Lin, and Brian C. Wilson. "Metronomic Photodynamic Therapy (mPDT) for Intracranial Neoplasm: Physiological, Biological and dosimetry considerations." In European Conference on Biomedical Optics. Washington, D.C.: OSA, 2003. http://dx.doi.org/10.1364/ecbo.2003.5142_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Isoardo, A., MM Ferrero, R. Dutto, E. Grande, L. Infante, M. Mondini, G. Perlo, M. Crea, M. Viglione, and C. Bonada. "DI-036 Metronomic chemotherapy with oral vinorelbine: epidemiological analysis and economic evaluation." In 22nd EAHP Congress 22–24 March 2017 Cannes, France. British Medical Journal Publishing Group, 2017. http://dx.doi.org/10.1136/ejhpharm-2017-000640.283.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Metronomica"

1

Xie, Ying, Xinjie Chen, and XiaoMin Wang. Efficacy evaluation of metronomic chemotherapy for breast cancer: a network meta analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, April 2021. http://dx.doi.org/10.37766/inplasy2021.4.0142.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Ferrone, Soldano. Combinational Targeting of Prostate Carcinoma Cells and Tumors Associated Pericytes with Antibody Based Immunotherapy and Metronomic Chemotherapy. Fort Belvoir, VA: Defense Technical Information Center, February 2010. http://dx.doi.org/10.21236/ada529444.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Ferrone, Soldano. Combinational Targeting of Prostate Carcinoma Cells and Tumors Associated Pericytes with Antibody Based Immunotherapy and Metronomic Chemotherapy. Fort Belvoir, VA: Defense Technical Information Center, February 2009. http://dx.doi.org/10.21236/ada551782.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Ferrone, Soldano, Barbara Foster, and Michael Moser. Combinatorial Targeting of Prostate Carcinoma Cells and Tumor Associated Pericytes with Antibody-Based Immunotherapy and Metronomic Chemotherapy. Fort Belvoir, VA: Defense Technical Information Center, March 2011. http://dx.doi.org/10.21236/ada551786.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Ferrone, Soldano, Barbara Foster, and Michael Moser. Combinational Targeting of Prostate Carcinoma Cells and Tumors Associated Pericytes with Antibody Based Immunotherapy and Metronomic Chemotherapy. Fort Belvoir, VA: Defense Technical Information Center, February 2008. http://dx.doi.org/10.21236/ada482376.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Chen, Xiaoyuan. Alpha-v Integrin Targeted PET Imaging of Breast Cancer Angiogenesis and Low-Dose Metronomic Anti-Angiogenic Chemotherapy Efficacy. Fort Belvoir, VA: Defense Technical Information Center, August 2008. http://dx.doi.org/10.21236/ada588970.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Chen, Xiaoyuan. Alpha-v Integrin Targeted PET Imaging of Breast Cancer Angiogenesis and Low-Dose Metronomic Anti-Angiogenic Chemotherapy Efficacy. Fort Belvoir, VA: Defense Technical Information Center, August 2006. http://dx.doi.org/10.21236/ada469375.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Chen, Xiaoyuan. Alpha-v Integrin Targeted PET Imaging of Breast Cancer Angiogenesis and Low-Dose Metronomic Anti-Angiogenic Chemotherapy Efficacy. Fort Belvoir, VA: Defense Technical Information Center, August 2007. http://dx.doi.org/10.21236/ada476052.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Metronomica' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography